The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trial.
Authors
Reck, MSocinski, M
Luft, A
Szczęsna, A
Dediu, M
Ramlau, R
Losonczy, G
Molinier, O
Schumann, C
Gralla, R
Bonomi, P
Brown, J
Soldatenkova, V
Chouaki, N
Obasaju, C
Peterson, P
Thatcher, Nick
Affiliation
Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, GermanyIssue Date
2016-03-12
Metadata
Show full item recordAbstract
Necitumumab, a second-generation, recombinant human immunoglobulin G1 epidermal growth factor receptor antibody in the phase 3 SQUIRE trial (NCT00981058), increased survival benefit for patients randomized to receive necitumumab plus gemcitabine-cisplatin compared with those who received gemcitabine-cisplatin. Here we characterize health-related quality of life (HRQoL) and tolerability results.Citation
The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE Trial. 2016: J Thorac OncolJournal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2016.03.002PubMed ID
26980471Type
ArticleLanguage
enISSN
1556-1380ae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2016.03.002